Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion - Wikidata - awgldk - TriplyDB

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

http://www.wikidata.org/entity/Q29617359

about

Evolutionary dynamics of cancer in response to targeted combination therapy Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Trial Watch Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations Resistant mechanisms to BRAF inhibitors in melanoma The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy New therapeutic strategies for BRAF mutant colorectal cancers Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression c-Met as a Target for Personalized Therapy Melanoma: oncogenic drivers and the immune system The utility of transposon mutagenesis for cancer studies in the era of genome editing.Targeting Breast Cancer Metastasis Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Exosomic microRNAs in the Tumor Microenvironment Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts Genetic instability in the tumor microenvironment: a new look at an old neighbor Evolutionary determinants of cancer Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Targeting melanoma by small molecules: challenges ahead Universes collide: combining immunotherapy with targeted therapy for cancer Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF The gastrointestinal tumor microenvironment Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads Adaptive resistance to targeted therapies in cancer Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression Pathways and therapeutic targets in melanoma A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction

P2860

Q21128788-FB8A5E1F-5E12-45B5-8DE3-16A6BBB6A1BE Q24303940-6497E891-999A-4FD2-8250-3D136FB47B18 Q24336818-040EDE66-85C2-4531-9693-B5822A983F2D Q24563539-A23CEFE8-8A2D-4010-868C-965FC8BCA145 Q24618653-60638DE9-D1E8-4894-97BE-C420E9620BFA Q24627664-E370AE72-07A0-41D4-87E5-9173981E41DF Q24632064-0731A8F4-54D4-4751-A3A4-A0D40A86FDB1 Q26739717-87FE6A7D-37D6-4FE0-98A3-F444D5B8CC63 Q26747247-E16CC765-2273-44AF-BA5F-25235DBD7356 Q26750420-1811127A-6A3E-4B8E-8A9C-06030A96E18C Q26771192-F7EA1D7E-6C90-4D72-8D84-D8DE2243D452 Q26772277-1E133C72-CB11-45CC-BD4C-F4B5FAC4DE5D Q26774159-77F85427-ACD1-4A9D-B63D-1D8304EB5285 Q26775189-5294C77B-13C0-418F-9936-81254CDCD92C Q26775483-BDDF42B2-F794-4EF2-8F48-78CB31BF2D9F Q26775598-2D502516-1326-4006-96B3-CD7575AE49AC Q26781762-75C2F759-EB97-4547-91C5-C33D4EC0D640 Q26783925-6EA98DF8-97E8-47DA-87A6-3DD7513E4982 Q26795609-20F54BDF-B093-43B9-A351-18F8FB6332F9 Q26795735-5946E64C-BC47-45DF-8D6C-AC07CAA83F63 Q26796309-173E5037-C69C-47E8-94D6-9461C6F43301 Q26799945-5F8A67F6-0886-4D6A-9C00-A29E9E0F9B8A Q26800007-23BF5584-CC92-4ED1-8C1F-6FA1564CD33F Q26801063-06120D1A-3B67-4CAA-BF92-C386CC56CB26 Q26801374-A653BFEE-D847-4C72-859B-6019F58BABDF Q26801710-136C1134-2ACB-4E35-9F5B-99AAD5F28B6E Q26824310-37B668FE-081C-4867-95C0-9FCBA2F356C9 Q26824642-A45025EB-FE61-4163-9C17-770FFFE40D6F Q26825316-B8480C28-A926-464E-B285-E0BF11CC3F45 Q26827212-1B65035C-8460-43AB-A8E7-D93B147C7B0B Q26827391-93C2822E-A2F9-486A-8044-0276D9A81860 Q26830075-6056CD42-C295-467B-840E-110214668128 Q26849316-89C8A0E1-CE81-4514-B96A-4B0348244EC8 Q26852716-739FF3CD-932C-448E-8EC8-3CFC777913EB Q26865736-28905802-F538-46E0-911F-F0118E530E46 Q27003534-0552AF7B-D5DD-4C98-8F00-4D6A030DE34E Q27011884-7B8B4702-A6B1-47F8-8D71-BCC330B8E826 Q27015224-80F53C50-722E-43CF-811B-73413EACDB36 Q27026323-5DB9051F-4E61-4382-BD64-657D839A9738 Q27312218-9FA7ABFA-5588-4D8D-A8A7-71137221DE49

P2860

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

http://www.wikidata.org/entity/Q29617359

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Tumour micro-environment elici ...... hibitors through HGF secretion

@ast

Tumour micro-environment elici ...... hibitors through HGF secretion

@en

type

label

Tumour micro-environment elici ...... hibitors through HGF secretion

@ast

Tumour micro-environment elici ...... hibitors through HGF secretion

@en

prefLabel

Tumour micro-environment elici ...... hibitors through HGF secretion

@ast

Tumour micro-environment elici ...... hibitors through HGF secretion

@en

P1433

Q29617359-22146115-CC99-44EB-8A50-B505044E9F20

P1476

Q29617359-BF517482-C112-42AF-87E8-C3A264883E93

P2093

Q29617359-0CD19FF9-F796-47E3-BCD7-EAC19D07A3D6

Q29617359-10507650-2AA1-438D-8B3C-FFA9B25CB48A

Q29617359-2017DA66-EED5-42D8-9FEC-5A91743BD299

Q29617359-3CE0E7E0-88B4-4817-A8A5-91DE091BCC2E

Q29617359-425AAA3D-04D1-4D89-9AE2-E14141FD18B5

Q29617359-45F17B23-FCF2-4A65-8CD7-059E2EF74CBB

Q29617359-65521C4F-09F2-4A44-BEFC-2633ED2612D0

Q29617359-6DB39144-4679-4AA1-8EDD-7053FCF868DC

Q29617359-71D994FE-AC9B-4BD3-884A-E5E4789A2746

Q29617359-7977B7CE-1536-4D2C-B3DE-AFB86A21C864

P2860

Q29617359-1AC1B8F9-E03B-4E32-94A8-A0C8F9D99F06

Q29617359-2257ADDD-CDB4-489A-AA23-B4C701C05E4D

Q29617359-263B22B6-C0D6-4A66-BEB3-3336342A6B3F

Q29617359-2B954F72-ABFB-4370-8204-B1F378951BA5

Q29617359-2E96AE9F-C6CC-49CB-BD76-FB103A7B1875

Q29617359-318D8C1F-EEF2-4D53-B658-54AB132DB809

Q29617359-3B7BEB60-85DF-4067-8D2B-6BFF1547ACEF

Q29617359-3C59A402-E9A5-4075-8E99-4C95C6BCBCA9

Q29617359-3D9613A1-91DC-432A-9768-932DDEA5EB38

Q29617359-53CDC2ED-C44F-4BE8-9E98-3FFA34B0188A

P2888

Q29617359-9AC17B9C-CE60-4124-B1CA-90745D3BD1D3

P304

Q29617359-C870B6F4-5641-4E2E-A6F7-3DAD4C7CD2FC

P31

Q29617359-7541986F-7D49-4FFE-9DF1-995907D5B8B1

P3181

Q29617359-468F650A-D6C9-4908-8AC4-37D03EEC932A

P356

Q29617359-559BE2A3-740F-46A8-BED4-E2038C32DC74

P407

Q29617359-F8DF1415-3977-4D4C-8CBF-A76A9DF9ADE2

P433

Q29617359-8D443DD6-58E0-488E-8F43-7842870D39F2

P478

Q29617359-DB5AFB16-8BC9-4745-B4AB-3777A9A1D6A5

P577

Q29617359-E0C05AFB-A199-42A8-8C67-46B70CEFC1BA

P5875

Q29617359-81FAA855-56B3-4624-90E0-56C7239A44AB

P6179

Q29617359-D09E29A7-FD15-494C-9F70-7A993C577EEB

P698

Q29617359-AAFAB056-3EF1-430E-9EB0-8D9C88D86881

P921

Q29617359-31E7A79B-9CAC-4074-9422-211ABA97EBCA

P932

Q29617359-C0B78A56-EA3F-42ED-A98D-69D7DB66D79E

P3181

P356

P1433

P1476

Tumour micro-environment elici ...... hibitors through HGF secretion

@en

P2093

Barzily-Rokni M

http://www.w3.org/2001/XMLSchema#string

Chapman PB

http://www.w3.org/2001/XMLSchema#string

Cooper ZA

http://www.w3.org/2001/XMLSchema#string

Davis A

http://www.w3.org/2001/XMLSchema#string

Du J

http://www.w3.org/2001/XMLSchema#string

Flaherty KT

http://www.w3.org/2001/XMLSchema#string

Frederick DT

http://www.w3.org/2001/XMLSchema#string

Golub TR

http://www.w3.org/2001/XMLSchema#string

Gould J

http://www.w3.org/2001/XMLSchema#string

Lo RS

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Microenvironmental regulation of metastasis

Fibroblasts in cancer

P2888

P304

500-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

309074

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE11183

http://www.w3.org/2001/XMLSchema#string

P407

P433

7408

http://www.w3.org/2001/XMLSchema#string

P478

487

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228324378

http://www.w3.org/2001/XMLSchema#string

P6179

1053677952

http://www.w3.org/2001/XMLSchema#string

P698

22763439

http://www.w3.org/2001/XMLSchema#string

P921

P932

3711467

http://www.w3.org/2001/XMLSchema#string